Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Leukemia & Lymphoma
|
March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
Kristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
British Journal of Haematology
|
March 5, 2019
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
Habte Yimer, Jason Melear, Edward Faber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Cancer Chemotherapy and Pharmacology
|
November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myeloma
Craig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
Blood
|
October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
John C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Leukemia & Lymphoma
|
June 22, 2022
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study
Habte Yimer, Jason Melear, Edward Faber, et al.
Leukemia & Lymphoma
|
October 29, 2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Thomas S Lin, Wendy Stock, Huiping Xu, et al.
Blood
|
January 15, 2008
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Syed-Rehan A Hussain, David M Lucas, Amy J Johnson, et al.
Plos One
|
November 13, 2010
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition
Wenjun Ni, Jia Ji, Zunyan Dai, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Leukemia & Lymphoma
|
March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
Kristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
British Journal of Haematology
|
March 5, 2019
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
Habte Yimer, Jason Melear, Edward Faber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Cancer Chemotherapy and Pharmacology
|
November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myeloma
Craig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
Blood
|
October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
John C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Leukemia & Lymphoma
|
June 22, 2022
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study
Habte Yimer, Jason Melear, Edward Faber, et al.
Leukemia & Lymphoma
|
October 29, 2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Thomas S Lin, Wendy Stock, Huiping Xu, et al.
Blood
|
January 15, 2008
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Syed-Rehan A Hussain, David M Lucas, Amy J Johnson, et al.
Plos One
|
November 13, 2010
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition
Wenjun Ni, Jia Ji, Zunyan Dai, et al.
Page
of 8